Aurinia Pharmaceuticals (AUPH) risk factors, FY2025 10-K

Aurinia Pharmaceuticals's FY2025 10-K, filed Feb 26, 2026, lists 30 risk factors in 7 groups. Against the prior year's 33: 2 new, 5 dropped, 9 substantially reworded.

Open AUPH in Gloom →
Aurinia Pharmaceuticals' chart, financials and news, free in your browser.Open AUPH in Gloom →
Risk factors listed
307 groups
New this year
2vs 33 last year
Dropped
5since the prior 10-K
Substantially reworded
9of those kept
Section length
7k wordsItem 1A

What the changes say

  • U.S. pharmaceutical trade-policy investigation creates new exposure for Canadian operations importing Swiss-manufactured products.
  • Aurinia emphasizes LUPKYNIS as its only approved product and sole source of net product sales.
  • Otsuka collaboration disclosures now detail $50 million upfront consideration, royalties, supply, and Lonza manufacturing services.
  • Aritinercept replaces AUR200 in development and regulatory risks, reflecting the candidate’s renamed identity.

What changed since the prior 10-K

New

  • NewRISKS RELATED TO GOVERNMENT REGULATION

    Changes or developments in U.S. economic laws or policies, including the reaction of other countries thereto, may have a material adverse effect on our business

    U.S. tariffs, pricing restrictions, or other trade measures could raise risks for Aurinia’s Swiss-to-U.S. pharmaceutical supply chain.

  • NewRISKS RELATED TO OWNERSHIP OF OUR COMMON SHARES

    We have never paid a dividend on our common shares

    Aurinia has never paid dividends, and uncertain LUPKYNIS results, expenses, and financing needs could limit shareholder returns or cause dilution.

Dropped

  • DroppedRISKS RELATED TO COMMERCIALIZATION

    (collectively, the “Otsuka Territories”) in exchange for: (i) a $50 million upfront cash payment; (ii) regulatory and commercial milestone payments; and (iii) royalties ranging from 10% to 20% on net sales in the Otsuka Territories

  • DroppedRISKS RELATED TO COMMERCIALIZATION

    We have reported on various commercial metrics relating to LUPKYNIS, and no single metric is indicative of, or directly correlated to, our current or future financial performance

  • DroppedRISKS RELATED TO FINANCIAL POSITION

    Our restructuring efforts and associated organizational changes may not adequately reduce our operating costs, may lead to additional workforce attrition and may cause operational disruptions

  • DroppedRISKS RELATED TO GOVERNMENT REGULATION

    any customer of the manufacturer, with certain exceptions for government programs, and pay prescription rebates to state Medicaid programs based on a statutory formula derived from reported pricing information

    Otsuka supply, manufacturing, and shared Lonza facility arrangements for LUPKYNIS.

  • DroppedRISKS RELATED TO OWNERSHIP OF OUR COMMON SHARES

    We have never paid a dividend on our common shares, and you should rely on price appreciation of our common shares for return on your investment

Reworded

  • 89% rewrittenRISKS RELATED TO COMMERCIALIZATION

    The commercial success of LUPKYNIS in certain ex-U.S. territories is dependent on the fulfillment of contractual obligations under our collaboration and licensing agreement and commercial supply agreement

    The risk now specifies Otsuka Territories, $50 million upfront consideration, 10%–20% royalties, and Aurinia’s LUPKYNIS supply and Lonza services.

    Was: The commercial success of LUPKYNIS in certain ex-U.S. territories is dependent on the fulfillment of contractual obligations under our out-license agreement and commercial supply agreement

  • 40% rewrittenRISKS RELATED TO FINANCIAL POSITION

    Our ability to use our net operating loss carryforwards and tax credit carryforwards to offset future taxable income may be subject to certain limitations. We may also be subject to other potential tax consequences

    No substantive change is shown; the net operating loss and tax-credit carryforward limitations remain unchanged.

  • 38% rewrittenRISKS RELATED TO DRUG DEVELOPMENT AND REGULATORY APPROVAL

    Our development of aritinercept may be delayed or halted

    The development candidate was renamed from AUR200 to aritinercept, and “good clinical practices” replaces “required clinical practices.”

    Was: Our development of AUR200 may be delayed or halted

  • 34% rewrittenRISKS RELATED TO GOVERNMENT REGULATION

    We are subject to various federal, state and foreign laws and regulations governing the health care industry that could result in substantial penalties for noncompliance

    The text is substantively unchanged in the excerpt, with minor capitalization and formatting differences.

  • 33% rewrittenRISKS RELATED TO PATENTS AND PROPRIETARY TECHNOLOGY

    LUPKYNIS’s market exclusivity periods will depend on the validity and enforceability of issued and pending patents covering LUPKYNIS

    The risk now states Aurinia has filed additional LUPKYNIS patent applications, rather than only planning to file them.

  • 31% rewrittenRISKS RELATED TO DRUG DEVELOPMENT AND REGULATORY APPROVAL

    Results from studies of aritinercept may not be sufficient to obtain regulatory approvals to market it on a timely basis, if at all

    The candidate was renamed from AUR200 to aritinercept, and “European Commission” is spelled out with its abbreviation.

    Was: Results from studies of AUR200 may not be sufficient to obtain regulatory approvals to market our product candidate on a timely basis, if at all

  • 31% rewrittenRISKS RELATED TO OWNERSHIP OF OUR COMMON SHARES

    The volume and trading price of our common shares may fluctuate significantly, and you may lose all or part of your investment

    The risk adds that share-price volatility may lead shareholders to bring securities class-action litigation.

  • 27% rewrittenRISKS RELATED TO OWNERSHIP OF OUR COMMON SHARES

    There can be no assurance that we will continue to repurchase Common Shares or that we will repurchase Common Shares at favorable prices

    The repurchase authorization increased by an additional $150 million on July 31, 2025, and the Company now evaluates transactions.

  • 23% rewrittenRISKS RELATED TO FINANCIAL POSITION

    Our overall financial performance may not meet our expectations

All 30 risk factors

Headings as the filing states them, in filing order.

RISKS RELATED TO COMMERCIALIZATION

  1. 01We are substantially dependent on the commercial success of LUPKYNIS
  2. 02Product liability or other lawsuits against us could cause us to incur substantial liabilities and reduce LUPKYNIS sales
  3. 03The commercial success of LUPKYNIS in certain ex-U.S. territories is dependent on the fulfillment of contractual obligations under our collaboration and licensing agreement and commercial supply agreement89% rewritten
  4. 04The commercial success of LUPKYNIS is dependent on pricing regulations and/or third-party coverage and reimbursement policies
  5. 05If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the U.S., we could be subject to additional reimbursement requirements, penalties, sanctions and fines

RISKS RELATED TO PATENTS AND PROPRIETARY TECHNOLOGY

  1. 06LUPKYNIS’s market exclusivity periods will depend on the validity and enforceability of issued and pending patents covering LUPKYNIS33% rewritten
  2. 07If our products or our product candidates infringe the rights of others, we could be subject to expensive litigation, become liable for substantial damages, be required to obtain licenses from others or be prohibited from selling our products or product candidates altogether
  3. 08Patent policy and rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents
  4. 09We may not be able to protect the confidentiality of our trade secrets

RISKS RELATED TO FINANCIAL POSITION

  1. 10Our overall financial performance may not meet our expectations23% rewritten
  2. 11Our ability to use our net operating loss carryforwards and tax credit carryforwards to offset future taxable income may be subject to certain limitations. We may also be subject to other potential tax consequences40% rewritten

RISKS RELATED TO DRUG DEVELOPMENT AND REGULATORY APPROVAL

  1. 12Drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies of aritinercept may not be predictive of future study results
  2. 13Results from studies of aritinercept may not be sufficient to obtain regulatory approvals to market it on a timely basis, if at all31% rewritten
  3. 14Our development of aritinercept may be delayed or halted38% rewritten
  4. 15Compliance with ongoing post-marketing obligations for LUPKYNIS may uncover new safety information that could give rise to a product recall, updated warnings or other regulatory actions
  5. 16Failure to obtain regulatory approval in international jurisdictions would prevent our products, our product candidates or any other products we or our current or future out-licensees may develop from being marketed abroad

RISKS RELATED TO OUR RELIANCE ON THIRD PARTIES

  1. 17The commercial success of LUPKYNIS and the clinical success of aritinercept will depend on our ability to obtain an uninterrupted supply from our contract manufacturers

RISKS RELATED TO GOVERNMENT REGULATION

  1. 18We are subject to various federal, state and foreign laws and regulations governing the health care industry that could result in substantial penalties for noncompliance34% rewritten
  2. 19Drugs approved by the FDA, EC and/or other regulatory agencies are subject to ongoing regulation
  3. 20Changes or developments in U.S. economic laws or policies, including the reaction of other countries thereto, may have a material adverse effect on our businessNew

RISKS RELATED TO OWNERSHIP OF OUR COMMON SHARES

  1. 21The volume and trading price of our common shares may fluctuate significantly, and you may lose all or part of your investment31% rewritten
  2. 22We have never paid a dividend on our common sharesNew
  3. 23There can be no assurance that we will continue to repurchase Common Shares or that we will repurchase Common Shares at favorable prices27% rewritten
  4. 24Our employees, consultants, contract manufacturing organizations, principal investigators, and clinical research organizations may engage in misconduct, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business
  5. 25Business interruptions resulting from geopolitical actions, natural disasters, public health crises or other catastrophic events could have an adverse impact on our business
  6. 26You may be unable to enforce actions against us, or certain of our officers under U.S. laws
  7. 27Our business and operations may be materially adversely affected in the event of computer system failures or security breaches
  8. 28Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
  9. 29Disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met
  10. 30Use of hazardous materials might expose us to risk in the form of damages

Other Aurinia Pharmaceuticals 10-Ks

  • FY2024 10-K risk factors
    33 risks

    Aurinia is heavily dependent on the commercial success of its sole approved product, LUPKYNIS, and the clinical development of AUR200. Restructurings in 2024 significantly reduced headcount by 25% and 45% to cut operating costs.

    Filed Feb 27, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.